Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medical composition for preventing and treating NITM and pharmaceutical application of medical composition

A composition and drug technology, applied in the field of medicine, can solve problems such as no effective treatment or prevention means, and insufficient attention

Active Publication Date: 2019-01-08
SHENYANG XINGQI PHARM CO LTD
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Regarding NITM, it has not yet attracted enough attention, and there is no corresponding effective treatment or prevention method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical composition for preventing and treating NITM and pharmaceutical application of medical composition
  • Medical composition for preventing and treating NITM and pharmaceutical application of medical composition
  • Medical composition for preventing and treating NITM and pharmaceutical application of medical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0108] Example 1: NITM treatment experiment

[0109] 1. Experimental drugs

[0110] Prepare 0.01% atropine sulfate eye drops with 0.9% saline, and adjust the pH to 6.0 with hydrochloric acid. Used for administration in the test group.

[0111] 2. Experimental method

[0112] Select 30 myopia patients aged 6-18 years. The selected eyes have diopters ranging from -0.50DS to -5.00DS, astigmatism ≤-1.0DC; initial NITM value ≥-0.25D; intraocular pressure is normal, not exceeding 21mmHg. Randomly divided into 2 groups, 15 cases in each group. The test group was dripped with the aforementioned experimental drugs, and the control group was dripped with 0.9% normal saline; each group was administered once a day, 1 drop per eye each time, and dripped into the conjunctival sac before going to bed for 6 months. Perform NITM detection at the set time, record the initial NITM value, NITM attenuation time, and the equivalent spherical power of the glasses worn to the best vision. The initial NIT...

Embodiment 2

[0135] Example 2: Study on the effect and side effects of different concentrations of atropine sulfate eye drops on NITM

[0136] 1. Experimental drugs

[0137] Use 0.9% normal saline to prepare eye drops of atropine sulfate with concentrations of 0.001%, 0.005%, 0.01%, 0.02%, 0.05%, 0.1%, 0.2%, and adjust the pH to 5.5 with hydrochloric acid. Used for administration in the test group.

[0138] 2. Experimental method

[0139] Select 120 myopia patients aged 6-18 years. The selected eyes have diopters ranging from -0.50DS to -5.00DS, astigmatism ≤-1.0DC; initial NITM value ≥-0.25D; intraocular pressure is normal, not exceeding 21mmHg. Randomly divided into 8 groups with 15 cases in each group. The 7 test groups were dripped with 0.9% saline solution of 0.001%, 0.005%, 0.01%, 0.02%, 0.05%, 0.1%, 0.2% atropine sulfate eye drops, and the control group was dripped with 0.9% saline; each group They were administered once a day, 1 drop per eye each time, and dropped into the conjunctiva...

Embodiment 3

[0154] Example 3: Study on the effect of atropine sulfate eye drops with different pH values ​​on NITM

[0155] 1. Experimental drugs

[0156] 0.9% sodium chloride solution was used to prepare 0.01% atropine sulfate eye drops, and the pH value was adjusted to 4.0, 4.5, 5.0, 5.5, 6.0, 6.5 with hydrochloric acid. Used for administration in the test group.

[0157] 2. Experimental method

[0158] Select 105 myopia patients aged 6-18 years. The selected eyes have diopters ranging from -0.50DS to -5.00DS, astigmatism ≤-1.0DC; initial NITM value ≥-0.25D; intraocular pressure is normal, not exceeding 21mmHg. Randomly divided into 7 groups, 15 cases in each group. The 6 test groups were instilled with the previously prepared atropine solution (pH values ​​were 4.0, 4.5, 5.0, 5.5, 6.0, 6.5), and the control group was instilled with 0.9% saline; each group was administered once a day, each time 1 drop per eye, instill in the conjunctival sac before going to bed for 2 weeks. NITM detection...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicines, and relates to a medical composition for preventing and treating NITM and a pharmaceutical application of the medical composition. Specifically, the medical composition is a medical composition for eyes, such as a preparation for eyes. Specifically, the medical composition disclosed by the invention comprises 0.001%-0.2% of atropine or pharmaceutical salt thereof, and one or more auxiliary materials acceptable in pharmacy, wherein the pH value of the medical composition is 4.0-6.5, the medical composition comprises 0.5%-5% of a pH regulation agent, and the pH regulation agent is selected from any one or more of sodium dihydrogen phosphate, disodium hydrogen phosphate, citric acid, citrate, boric acid and borate. The medical composition disclosed by the invention can effectively treat and / or prevent NITM, and has favorable application prospects.

Description

Technical field [0001] The invention belongs to the field of medicine and relates to a pharmaceutical composition for preventing and treating NITM and its medical use. Specifically, the pharmaceutical composition is an ophthalmic pharmaceutical composition such as an ophthalmic preparation. Background technique [0002] Myopia means that parallel light rays from a distance are focused in front of the photoreceptor layer of the retina without the adjustment function. In short, when the eye is at rest, parallel light rays are focused in front of the retina. How far away from 0D the refractive index is to be considered myopia, there is no uniform international standard for this. It is more practical to take -0.25D or 0.50D as the standard (see "Myopia", Hu Daning and other editors, People's Medical Publishing House, first edition, June 2009, page 3). [0003] The Refractive Optics Group of the Ophthalmology Branch of the Sinochem Medical Association formulated the "Definition and Cl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K31/46A61K47/02A61K47/04A61K47/12A61K47/38A61P27/10
CPCA61K47/02A61K47/12A61K47/38A61P27/10A61K9/0048A61K31/46A61K9/08A61K47/183A61K47/186A61K47/36
Inventor 刘继东王宁利郭雷杨强高坤李林蔚顾红孙洋付乐
Owner SHENYANG XINGQI PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com